EUVIMEDEUVIMED entdecken
Open Access

Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality

Nazlım Aktuğ Demir iD, Fatih Temoçin iD, Onur Ural iD, Ezgi Gülten iD, Ayşe Seza İnal iD, Çigdem Kader iD, Yasemin Ersoy iD, Ali Asan iD, Pınar Aysert Yıldız iD, Şua Sümer iD, Eyüp Arslan iD, Yakup Gezer iD und 10 weitere

Infectious Diseases and Clinical Microbiology · 15.12.2025 · 411

DOI: 10.36519/idcm.2025.744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infectious Diseases and Clinical Microbiology, online erschienen am 15.12.2025. Verfasst von Nazlım Aktuğ Demir und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Infectious Diseases, Selcuk University School of Medicine, Konya, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Multidrug-resistant Gram-negative bacteria cause difficult-to-treat infections associated with high mortality. Carbapenems are widely used; however, their overuse has led to the emergence of carbapenem-resistant bacteria. This study aimed to evaluate the indications, clinical and microbiological efficacy, and side effects of ceftazidime-avibactam (CAZ-AVI) and to identify factors influencing mortality, based on data from a large multicenter patient cohort in Türkiye. Materials and Methods: Patients with carbapenem-resistant but CAZ-AVI-susceptible Gram-negative bacterial infections who received CAZ-AVI treatment were retrospectively reviewed.

Results

A total of 1245 patients were included. The most common indication for CAZ-AVI use was hospital-acquired pneumonia (47.8%). Klebsiella pneumoniae was the predominant pathogen (81.3%). CAZ-AVI was used as a monotherapy in 80% of cases. Clinical side effects were observed in 8 (0.64%) patients, while laboratory abnormalities occurred in 73 (5.86%). The 7-day, 14-day, and 28-day all-cause mortality rates were 13.8%, 28.9%, and 45.2%, respectively. Microbiological eradication was achieved in 82.3% of patients. Higher Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores at admission, requirement for continuous renal replacement therapy, mechanical ventilation, and elevated C-reactive protein levels were identified as independent risk factors for mortality.

Conclusion

This large multicenter real-world analysis demonstrates that CAZ-AVI is an effective treatment option for severe infections with high mortality, such as those caused by carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa.

Schlagwörter

Stichwörter der Autor:innen

Ceftazidime-avibactamcarbapenem-resistantmortality determinants

Autor:innen und Institutionen

  • Department of Clinical Microbiology and Infectious Diseases, Selcuk University School of Medicine, Konya, Türkiye.
  • Department of Clinical Microbiology and Infectious Diseases, Ondokuz Mayıs University School of Medicine, Samsun, Türkiye.
  • Department of Clinical Microbiology and Infectious Diseases, Ankara University School of Medicine, Ankara, Türkiye.
  • Department of Clinical Microbiology and Infectious Diseases, Çukurova University School of Medicine, Adana, Türkiye.
  • Department of Clinical Microbiology and Infectious Diseases, Yozgat Bozok University School of Medicine, Yozgat, Türkiye.
  • Department of Clinical Microbiology and Infectious Diseases, İnönü University School of Medicine, Malatya, Türkiye.

ORCID-Profile: Nazlım Aktuğ Demir, Fatih Temoçin, Onur Ural, Ezgi Gülten, Ayşe Seza İnal, Çigdem Kader, Yasemin Ersoy, Ali Asan, Pınar Aysert Yıldız, Şua Sümer, Eyüp Arslan, Yakup Gezer, Güle Çınar, Elif Mukime Sarıcaoğlu, Tuba Tatlı-Kış Tatlı Kış, Serap Özçimen, Barçın Öztürk, Burak Sarıkaya, Merve Türkmen, Tuba Kuruoğlu, Ceren Atasoy Tahtasakal, Emel Yılmaz

Zitieren

APA

Aktuğ Demir, N., Temoçin, F., Ural, O., Gülten, E., İnal, A. S., Kader, Ç., Ersoy, Y., Asan, A., Aysert Yıldız, P., Sümer, Ş., Arslan, E., Gezer, Y., Çınar, G., Sarıcaoğlu, E. M., Tatlı Kış, T. T., Özçimen, S., Öztürk, B., Sarıkaya, B., Türkmen, M., …, & Yılmaz, E. (2025). Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality. Infectious Diseases and Clinical Microbiology, 411. https://doi.org/10.36519/idcm.2025.744

Vancouver

Aktuğ Demir N, Temoçin F, Ural O, Gülten E, İnal AS, Kader Ç, et al. Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality. Infectious Diseases and Clinical Microbiology. 2025:411. doi:10.36519/idcm.2025.744

BibTeX
@article{AktuDemir2025,
  author = {Aktuğ Demir, Nazlım and Temoçin, Fatih and Ural, Onur and Gülten, Ezgi and İnal, Ayşe Seza and Kader, Çigdem and Ersoy, Yasemin and Asan, Ali and Aysert Yıldız, Pınar and Sümer, Şua and Arslan, Eyüp and Gezer, Yakup and Çınar, Güle and Sarıcaoğlu, Elif Mukime and Tatlı Kış, Tuba Tatlı-Kış and Özçimen, Serap and Öztürk, Barçın and Sarıkaya, Burak and Türkmen, Merve and Kuruoğlu, Tuba and Atasoy Tahtasakal, Ceren and Yılmaz, Emel},
  title = {Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality},
  journal = {Infectious Diseases and Clinical Microbiology},
  year = {2025},
  pages = {411},
  doi = {10.36519/idcm.2025.744}
}
Kostenlos starten →